Navigation Links
Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
Date:4/7/2008

Results Reported at American Association for Dental Research Meeting

DURHAM, N.C., April 7, 2008 /PRNewswire/ -- Parion Sciences, Inc., a privately-held, development-stage pharmaceutical company dedicated to treating diseases resulting from the failure of the body's mucosal defenses, today announced preliminary results from a Phase I clinical safety study of a novel sodium channel blocker, P-552-02, as a topical therapy for dry mouth associated with primary Sjogren's syndrome. The preliminary results of the study showed that P-552-02 was safe and well tolerated, both locally in the oral cavity and systemically. No side effects or other safety issues were reported in the study. The results were reported on April 4 by Athena Papas, DMD, Ph.D., Professor at Tufts University School of Dental Medicine at the Annual Meeting of the American Association for Dental Research.

The trial was a 28-day, 30-patient, randomized, double-blind, placebo- controlled, crossover study designed to assess the effect of a six-time daily oral rinse formulation of P-552-02 versus placebo on oral and systemic safety parameters and the symptoms of dry mouth. The primary efficacy endpoint, a global improvement in the "feeling of dry mouth" as determined by a single retrospective "recall" report at day 28, was not met. However, an assessment of "global change in dry mouth" as determined by the change in visual analog scale (VAS) measurements 12 hours after dosing at day 7 and day 28 revealed significant improvement in the global dry mouth scores. VAS scores that measured the change at day 28 in mouth dryness, tongue dryness and ability to sleep also indicated that subjects improved on P-552-02 compared to placebo. The work was funded by Parion Sciences under a clinical study agreement with Tufts University.

"We are very encouraged with the outcome of this study. The improvements seen in this safety study, with the low dose and small sample size, demonstrate the potential of this drug candidate to bring relief to a quality of life issue faced daily by these patients," said M. Ross Johnson, Parion Chief Executive Officer. "Based on these results, we plan to proceed with a Phase I/IIA study designed to test the efficacy of higher concentrations of P-552-02 delivered in a spray formulation and dosing at different intervals, and to pursue other potential indications."

Epithelial sodium channel blockers, such as P-552-02, are unique therapeutic agents that stimulate and maintain hydration on the body's mucosal surfaces, including those on the lung, mouth, nose, eye and gastrointestinal tract. Restoring the hydration of mucosal surfaces in the mouth addresses the fundamental problem that causes the extreme dryness of Sjogren's syndrome.

Sjogren's syndrome is a chronic disorder that occurs when a person's normally protective immune system attacks and destroys moisture-producing glands, including the salivary and tear glands. There are currently no specific topical pharmaceutical medications to alleviate the symptoms of dry mouth associated with Sjogren's syndrome, which can cause difficulty with chewing and swallowing, decreased sense of taste, hoarseness, coughing and an increase in dental cavities.

About Parion Sciences

Based in Durham, NC, Parion Sciences is a privately-held, development- stage pharmaceutical company that is leveraging its proprietary small molecule chemistry and epithelial biology expertise to discover and develop an innovative pipeline of therapies for diseases resulting from the failure of the body's mucosal defenses, including Sjogren's syndrome, dry eye, certain pulmonary diseases, and diverticulitis and other gastrointestinal diseases, as well as biodefense applications. Parion's lead product candidate, P-552-02, has completed a Phase I clinical trial in Sjogren's syndrome and a Phase II clinical trial in cystic fibrosis. In August 2007, Parion announced a collaboration with Gilead Sciences focused on developing drug candidates for pulmonary diseases utilizing Parion's expertise in epithelial sodium channel blockers. Parion was founded based on technology from University of North Carolina, Chapel Hill (UNC-CH). For more information, please visit http://www.parion.com


'/>"/>
SOURCE Parion Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
6. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
7. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
11. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/30/2017)... Therapix Biosciences Ltd. (Nasdaq: TRPX), a ... development of cannabinoid-based drugs, today announced that the ... three upcoming scientific and investor conferences in June: ... ... Wednesday, June 7 ...
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... Torrance dentist, Dr. Robert Mondavi DDS ... the most noticeable aspects of a person’s appearance. A healthy, radiant smile can make ... beautiful, balanced teeth, everyone can have the smile of their dreams with cosmetic dentistry. ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... leakage is revolutionizing the way women look and feel about themselves and their ... of female sexual dysfunction and urinary leakage head on with a ground breaking ...
(Date:6/25/2017)... ... 2017 , ... FCPX LUT Vintage Volume 2 for Final Cut Pro X ... Volume 2 contains 60 different color-grade presets, giving editors multiple options for adding different ... single out subjects, plus much more. FCPX LUT Vintage Volume 2 is designed for ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... TX (PRWEB) , ... June 24, 2017 , ... The ... to spend time outdoors. Home and business owners should be aware that the summer ... the lake. In fact, mechanical locks and keys can be negatively affected from direct ...
Breaking Medicine News(10 mins):